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Abstract
A novel virus, designated swine hepatitis E virus (swine HEV), was identified in pigs. Swine HEV crossreacts
with antibody to the human HEV capsid antigen. Swine HEV is a ubiquitous agent and the majority of swine
≥3 months of age in herds from the midwestern United States were seropositive. Young pigs naturally infected
by swine HEV were clinically normal but had microscopic evidence of hepatitis, and developed viremia prior
to seroconversion. The entire ORFs 2 and 3 were amplified by reverse transcription–PCR from sera of
naturally infected pigs. The putative capsid gene (ORF2) of swine HEV shared about 79–80% sequence
identity at the nucleotide level and 90–92% identity at the amino acid level with human HEV strains. The
small ORF3 of swine HEV had 83–85% nucleotide sequence identity and 77–82% amino acid identity with
human HEV strains. Phylogenetic analyses showed that swine HEV is closely related to, but distinct from,
human HEV strains. The discovery of swine HEV not only has implications for HEV vaccine development,
diagnosis, and biology, but also raises a potential public health concern for zoonosis or xenozoonosis
following xenotransplantation with pig organs.
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ABSTRACT A novel virus, designated swine hepatitis E
virus (swine HEV), was identified in pigs. Swine HEV cross-
reacts with antibody to the human HEV capsid antigen. Swine
HEV is a ubiquitous agent and the majority of swine >3
months of age in herds from the midwestern United States
were seropositive. Young pigs naturally infected by swine HEV
were clinically normal but had microscopic evidence of hep-
atitis, and developed viremia prior to seroconversion. The
entire ORFs 2 and 3 were amplified by reverse transcription–
PCR from sera of naturally infected pigs. The putative capsid
gene (ORF2) of swine HEV shared about 79–80% sequence
identity at the nucleotide level and 90–92% identity at the
amino acid level with human HEV strains. The small ORF3 of
swine HEV had 83–85% nucleotide sequence identity and
77–82% amino acid identity with human HEV strains. Phy-
logenetic analyses showed that swine HEV is closely related to,
but distinct from, human HEV strains. The discovery of swine
HEV not only has implications for HEV vaccine development,
diagnosis, and biology, but also raises a potential public
health concern for zoonosis or xenozoonosis following xeno-
transplantation with pig organs.
Hepatitis E occurs predominantly in developing countries of
Asia and Africa, but has also been the cause of epidemics in
Mexico (1). The disease generally affects young adults and has
a very high mortality rate, up to 20%, in infected pregnant
women (1–4). Hepatitis E has rarely been reported in devel-
oped countries, and most of those cases have been imported (1,
4–6). The causative agent, hepatitis E virus (HEV), is trans-
mitted primarily by the fecal–oral route, often through con-
taminated water (1, 4). The availability of sensitive serological
tests for HEV has permitted detailed assessment of the
prevalence of HEV infection (7, 8). In regions where HEV is
endemic, anti-HEV have been detected in sera from conva-
lescent individuals, as well as from the general population (1,
3). Although hepatitis E is not endemic in the United States
and other developed countries, anti-HEV was found in a
significant proportion, up to 28% in some areas, of healthy
individuals in these countries (7, 9). It is not clear whether the
anti-HEV detected in the developed countries represents
infection with a nonpathogenic HEV strain or crossreactivity
with a related agent.
It has been reported that anti-HEV is acquired naturally in
primates and swine (1, 10), suggesting that these species have
been exposed to HEV or a related agent, and that hepatitis E
might be a zoonotic disease. The role of swine in HEV
transmission is not clear, although domestic swine were re-
ported to be susceptible to infection with a human HEV strain
(11). Here we report the first identification of an animal strain
of HEV. We designated this virus swine hepatitis E virus
(swine HEV) to distinguish it from human HEV.
MATERIALS AND METHODS
Serum Samples. Serum samples were obtained from swine
of various ages in 15 commercial herds and 1 specific-
pathogen-free (SPF) herd in the midwestern United States
(Table 1).
Preparation of HEV Putative Capsid Antigen. Insect cells
were infected with recombinant baculovirus containing the
putative capsid gene (ORF2) sequence of a Pakistani strain of
HEV, Sar55 (8). A 55-kDa recombinant protein expressed
from a recombinant baculovirus containing ORF2 was puri-
fied from insect cells (8) and used for the standard ELISA. The
ORF2 recombinant protein was further purified by HPLC
liquid chromatography.
Generation of Hyperimmune Swine Antibody to HEV. Two
3-week-old SPF swine were immunized intramuscularly with
50 mg of HPLC-purified ORF2 recombinant protein mixed
with Freund’s incomplete adjuvant. Booster immunizations
were given at 2 and 4 weeks after the first immunization. Sera
obtained before immunization and weekly for 9 weeks after
immunization were used to develop an ELISA (see below).
ELISA for Anti-HEV in Swine. The standard ELISA for
anti-HEV in swine was performed essentially as described for
anti-HEV in chimpanzees (8, 12), except that the secondary
antibody was replaced with peroxidase-labeled goat anti-swine
IgG (Kirkegaard & Perry Laboratories). All of the swine
serum samples were tested in duplicate. Preimmune and
hyperimmune anti-HEV positive swine sera were included as
negative and positive controls, respectively.
Blocking ELISA was used to confirm the results of the
standard ELISA on selected anti-HEV positive and negative
serum samples. The blocking ELISA for anti-HEV in swine
was performed essentially as described (13) except that the
competing sera were from swine. The ORF2 protein of strain
Sar55 was used for affinity purification of anti-HEV from
convalescent serum of a chimpanzee exposed twice to HEV
(8). The affinity-purified chimpanzee anti-HEV was conju-
gated with horseradish peroxidase by a custom service
(ViroStat, Portland, ME) and used for the blocking ELISA
(13). A serum sample was considered positive in the blocking
ELISA if the OD value was reduced by $50% compared with
the unblocked sample.
Prospective Study. Twenty-one sows from a commercial
herd were tested for IgG anti-HEV. Subsequently, 20 piglets
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(10 male and 10 female) were chosen from those born to
seronegative sows (6 piglets) and to seropositive sows with a
lower titer (6 piglets) or higher titer (8 piglets) of IgG
anti-HEV. These 20 study piglets were tagged and mixed with
other piglets from approximately 50 sows in the herd, and were
commingled in 2 rooms in a nursery building. Piglets within a
room were separated into pens by fences that allowed for
nose-to-nose contacts. By the age of about 10 weeks, all piglets
in the nursery building were moved to an empty finishing
building that had been disinfected.
Blood samples and nasal and rectal swabs from the 20 study
piglets were collected in alternate weeks from 2 weeks onward,
and weekly after 14 weeks of age. The serum samples were
tested for anti-HEV, and four piglets with an increasing ELISA
OD value were sacrificed. Samples of 19 different tissues and
organs were collected during necropsy, fixed in 10% neutral
buffered formalin, and processed for routine histologic exam-
ination.
Degenerate Primers for Reverse Transcription–PCR (RT-
PCR). The sequences of 10 human HEV strains were aligned
with a GeneWorks program (IntelliGenetics). Based on this
alignment, two sets of degenerate primers were designed and
synthesized to amplify two different regions of the capsid gene.
The primer positions indicated below are relative to the
published sequence of a Burmese HEV strain (14). Set one
primers: external 3156 [forward, position 5687–5708, 59-
AAT(C)TATGCC(A)CAGTACCGGGTTG-39] and 3157
(reverse, position 6395–6417, 59-CCCTTATCCTGCTGAG-
CATTCTC-39), and internal 3158 [forward, position 5972–
5993, 59-GTT(C)ATGC(T)TT(C)TGCATACATGGCT-39]
and 3159 [reverse, position 6298–6319, 59-AGCCGACGAAA-
TC(T)AATTCTGTC-39]. Set two primers: external 3160 [for-
ward, position 6578 – 6600, 59-GCCGAGTAT(C)GAC-
CAGTCCACTTA-39] and 3161 [reverse, position 7105–7127,
59-AT(C)AACTCCCGAGTTTTACCCACC-39], and inter-
nal 3162 [forward, position 6645–6667, 59-TGGTT(G)AAT-
GTT(A)GCGACC(T)GGCGCG-39] and 3163 [reverse, posi-
tion 7063–7085, 59-GCTCAGCGACAGTA(T)GACTG-
G(A)AAA-39].
RNA Extraction and RT-PCR. Total RNA was extracted by
TriZol reagent (GIBCO/BRL) from 100 ml of serum obtained
1 or 2 weeks before seroconversion from piglets in the pro-
spective study. Total RNA was then reverse transcribed with
one of the two degenerate primers by using SuperScript II
reverse transcriptase (GIBCO/BRL) at 42°C for 1 hr, and the
resulting cDNA was amplified by PCR using ampliTaq Gold
polymerase (Perkin–Elmer). The PCR reaction was carried
out for 39 cycles of denaturation at 94°C for 1 min, annealing
at 42°C for 1 min, and extension at 72°C for 2 min, followed by
a nested PCR using 10 ml of the first round PCR product with
a nested set of degenerate primers.
Amplification of the Entire ORFs 2 and 3 of Swine HEV.
After the first PCR fragment was amplified and sequenced, we
designed two sets of primers with a swine HEV-specific primer
at one end and a degenerate primer at the other end (primer
sequences not shown). RT-PCR with these primers was per-
formed essentially as described above. The entire ORFs 2 and
3 of swine HEV were amplified in this way by walking along
the genome in both directions.
Sequence Analysis. The PCR fragments were cut from 1%
agarose gels and purified with a Geneclean Kit (Bio 101). Both
strands were sequenced with an automated DNA sequencer.
The sequences were analyzed by the GENEWORKS program.
Phylogenetic analyses were conducted with the aid of the PAUP
software package, version 3.1.1 (David L. Swofford, Illinois
Natural History Survey, Champaign).
RESULTS
Standardization of an ELISA for Swine Anti-HEV. To
establish a reliable serological test for anti-HEV in swine, we
first generated hyperimmune antisera by immunizing two SPF
pigs with recombinant HEV ORF2 antigen. IgG anti-HEV was
first detected at 2 and 3 weeks postimmunization and reached
peak ELISA titers of 1024 at weeks 3 and 4 after immunization,
respectively. The anti-HEV titer remained at 1024 until the end
of the 9-week experiment. An ELISA for swine anti-HEV was
subsequently standardized by using the preimmune and hy-
perimmune swine sera along with 34 normal sera from swine
raised in laboratory environments and from swine in an SPF
herd. The ELISA cutoff value was set at 99% confidence
bounds, based on the frequency distribution of the absorbance
values of normal sera. The cutoff value was approximately 2.5
SD above the mean absorbance value of the normal sera.
Serological Evidence in Swine for Infection with an Agent
Related to HEV. The prevalence of anti-HEV in commercial
swine herds in the midwestern United States was assessed by
the standardized ELISA. Surprisingly, IgG anti-HEV was
found in a majority of swine $3 months of age in herds in the
midwestern United States, where human hepatitis E is not
endemic; however, most swine #2 months of age were sero-
negative (Table 1). None of the 10 adult swine from an SPF
herd was seropositive (Table 1). To further validate the
serology results, we performed a blocking ELISA on selected
anti-HEV positive and negative swine sera. Similar results
were obtained in the blocking ELISA and the standard ELISA.
The HEV antigen used in ELISA was expressed in insect cells;
therefore, we also included insect cells infected with baculo-
virus lacking the HEV sequence as a negative antigen control
and HPLC-purified HEV recombinant antigen as a positive
antigen control. There was little or no reaction between the
swine serum samples and the insect cells infected with the
baculovirus lacking the HEV sequence. Thus, the swine anti-
HEV reacted specifically with the human HEV capsid antigen
Table 1. IgG anti-HEV prevalence in swine from commercial
herds in the United States
Herd Age
No. of
swine tested
No. of swine
with anti-HEV (%)
A 6 wk 8 0 (0)
12 wk 8 0 (0)
20 wk 8 8 (100)
26 wk 8 5 (63)
Adult 25 14 (56)
B 3–4 wk 8 0 (0)
5–6 wk 8 0 (0)
7–8 wk 8 0 (0)
13 wk 12 10 (83)
6 mo 8 8 (100)
Adult 17 16 (94)
C 2 mo 8 1 (13)
3 mo 8 8 (100)
4 mo 8 4 (50)
5 mo 8 8 (100)
Adult 8 8 (100)
D 2 mo 10 2 (20)
E 6 mo 10 10 (100)
F 6 mo 10 10 (100)
G 6 mo 10 10 (100)
H 8 mo 10 10 (100)
I .1 yr 10 10 (100)
J 1–2 yr 10 10 (100)
K 1–3 yr 10 10 (100)
L 2 yr 10 10 (100)
M 2–3 yr 10 10 (100)
N Adult 19 15 (79)
O Adult 6 5 (83)
P* Adult 10 0 (0)
*Specific-pathogen-free (SPF) swine herd.
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in the standard ELISA and competed with anti-HEV in
convalescent chimpanzee serum in the blocking ELISA. These
data strongly suggested that a ubiquitous swine agent, anti-
genically related to human HEV, was circulating in the general
swine population.
Natural Infection of Swine in a Commercial Herd. In an
attempt to identify this putative HEV-related agent in pigs, a
prospective study was conducted in a commercial swine herd
in the midwestern United States. Consistent with our seroepi-
demiological results, 18 of 21 pregnant sows from this herd
tested positive for anti-HEV. Piglets born to seronegative sows
were seronegative at 2 weeks of age, and piglets born to
seropositive sows with a lower titer of IgG anti-HEV also
scored as seronegative, but had a comparatively high ELISA
OD value for IgG anti-HEV (Table 2). In contrast, piglets born
to seropositive sows with a higher titer of IgG anti-HEV were
positive at 2 weeks of age for IgG anti-HEV (Table 2), but not
for IgM anti-HEV. The level of IgG anti-HEV in seropositive
piglets decreased dramatically within a few weeks after birth
and had disappeared by the age of 8 or 9 weeks (Table 2, Fig.
1). Clearly, the anti-HEV detected in these newborns repre-
sented maternal antibody as evidenced by the correlation
between the levels of anti-HEV in 2-week-old piglets and in
their dams (Table 2), and from the fact that the anti-HEV
belonged to the IgG class. However, after the maternal anti-
body had waned, most of the piglets developed their own
antibodies to HEV. One piglet seroconverted to anti-HEV at
the age of 14 weeks, followed within a few weeks by serocon-
version of piglets in other pens housed in the same finishing
building. The pattern of anti-HEV appearance, starting with
piglets grouped near the first seropositive piglet, then followed
by more distal ones, was consistent with seroconversion in-
duced by an infectious agent (data not shown). By 21 weeks of
age, 16 of the 20 study piglets had seroconverted. Two other
piglets were necropsied prior to seroconversion and one piglet
died of an unknown cause. The only remaining seronegative
piglet had a rising ELISA OD value, but it was still below the
cut-off value at the end of the 21 week study. The level of IgG
anti-HEV increased steadily for several weeks after serocon-
version (Fig. 1). IgM anti-HEV, indicating a newly contracted
infection with this putative HEV-related agent, was also
detected in all piglets that seroconverted to IgG anti-HEV.
The level of IgM anti-HEV peaked about 1 week earlier than
that of IgG anti-HEV and decreased rapidly over about 1–2
weeks (Fig. 1).
Clinical illness was not observed in the piglets. Four piglets
believed to be at an early stage of infection were necropsied
during the study. Except for a gross lung lesion consistent with
a bacterial pneumonia in one piglet, other gross lesions were
not apparent in 19 different tissues and organs examined
during necropsy. Microscopically, all four piglets necropsied
had evidence of hepatitis characterized by mild to moderate
multifocal and periportal lymphoplasmacytic hepatitis with
mild focal hepatocellular necrosis (Fig. 2). In addition, all
piglets had lymphoplasmacytic enteritis, and three piglets also
had mild multifocal lymphoplasmacytic interstitial nephritis.
Syncytial cells were also noticed in the tonsils and Peyer’s
patches of one piglet (data not shown).
Genetic Characterization of the Swine HEV. Because the
swine anti-HEV reacted so strongly with the capsid protein of
human HEV, it was probable that swine HEV shared nucle-
otide sequence similarity with human HEV. Therefore, two
sets of degenerate primers derived from the HEV putative
capsid gene were used to attempt the amplification of the swine
HEV genome by RT-PCR of serum samples obtained 1 and 2
weeks before seroconversion. A fragment representing part of
the swine HEV genome (Fig. 3) was first amplified by a nested
FIG. 1. Seroconversion of piglets to anti-HEV. Anti-HEV re-
sponses of three representative piglets are presented. (A) Piglet born
to a seropositive sow with a high titer of IgG anti-HEV. (B) Piglet born
to a seropositive sow with a lower titer of IgG anti-HEV. (C) Piglet
born to a seronegative sow. The ELISA OD value of IgG anti-HEV in
breeder sows is indicated (S).
Table 2. Seroconversion of piglets to anti-HEV in a commercial
herd: A prospective study
Piglet
no.
Sow
ELISA
OD*
Piglet ELISA
OD,* wk
Age
seroconverted,
wk2 8 or 9
15 0.908 0.550 0.036 †
16 0.908 0.522 0.039 19
17 0.908 0.501 0.066 ‡
18 1.011 0.822 0.103 †
19 1.011 1.264 0.148 15
20 1.011 0.979 0.146 §
1 0.692 0.128 0.024 18
2 0.692 0.211 0.071 21
3 0.692 0.157 0.052 20
4 0.692 0.114 0.026 18
5 0.431 0.107 0.065 18
6 0.431 0.216 0.059 21
7 0.424 0.113 0.073 16†
8 0.424 0.195 0.093 15
9 0.209 0.047 0.050 18
10 0.209 0.079 0.090 19
11 0.209 0.047 0.039 19
12 0.245 0.057 0.061 14
13 0.245 0.056 0.038 16
14 0.245 0.057 0.012 20†
*ELISA cut-off value, 0.3.
†Necropsied.
‡Remained seronegative at 21 weeks of age.
§Death due to unknown cause.
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PCR with primer set 3158 and 3159. Sequence information
confirmed that this initial PCR fragment was specific for swine
HEV and represented part of the ORF2.
Sequence Analyses of Swine HEV ORFs 2 and 3. Analyses
of the complete ORFs 2 and 3 sequences revealed that swine
HEV is closely related to, although distinct from, human HEV
strains. In the putative capsid gene (ORF2), swine HEV shares
with human HEV strains about 79–80% sequence identity at
the nucleotide level, and about 90–92% identity at the amino
acid level (Table 3, Fig. 4). However, the relatively high amino
acid identity between swine and human HEV is significantly
lower than the amino acid identity (97–99%) among human
HEV strains with the exception of the Mexican strain. The
Mexican strain of HEV also displayed greater sequence di-
vergence of about 92–93% amino acid identity with other
human HEV strains (Table 3). However, the genetic distances
between swine HEV and the Mexican strain of HEV are
comparable to those between swine HEV and other human
HEV strains, indicating that swine HEV is also distinct from
the Mexican HEV (Table 3, Fig. 4). These data suggested that
we had identified a previously unrecognized swine virus
belonging to the same family as human HEV.
The small ORF3 of swine HEV had about 83–85% sequence
identity at the nucleotide level with human HEV strains, but
only 77–82% identity at the amino acid level (Table 3). The
human HEV strains also displayed a lower percentage of
identities at the amino acid level than that at the nucleotide
level (Table 3). Most of the amino acid variations in ORF3
were clustered in a hypervariable region consisting of 17 amino
acid residues near the carboxyl terminus (Fig. 4). In addition,
the ORF3 of swine HEV had a single amino acid deletion near
the amino terminus (Fig. 4).
The evolutionary relationships between swine and human
HEV were determined on the basis of the complete nucleotide
sequences of ORFs 2 and 3. The resulting phylogenetic tree
revealed that human HEV strains were represented by at least
two genotypes. The first genotype was represented by the
Mexican strain and the second genotype by the other human
HEV strains (Fig. 5). Phylogenetically, swine HEV is unique,
the most divergent of the HEV strains compared, and repre-
sents the first member of a third genotype (Fig. 5).
DISCUSSION
We have identified a novel HEV in pigs by documenting
seroconversion of pigs to anti-HEV, sequence similarity to
FIG. 2. Liver sections from a naturally infected piglet (no. 14). (A)
Multifocal lymphoplasmacytic and necrotizing hepatitis with randomly
distributed foci of hepatocellular swelling and vacuolation (arrow) and
foci of necrosis (arrowhead) with lymphoplasmacytic sinusoidal and
periportal infiltrates (310). (B) Foci of hepatocellular necrosis (ar-
row) and lymphoplasmacytic inflammation (3400). Hematoxyliny
eosin staining.
FIG. 3. Amplification of swine HEV-specific fragment by RT-
PCR. Serum samples from two piglets (nos. 4 and 14) obtained 1 week
before (21) and the week of (0) seroconversion in a prospective study
were used for RT-PCR of a 344 bp fragment. Serum samples obtained
at the same time (weeks 19 and 20) after birth from a seronegative
piglet (no. 15) were also included. L, molecular weight marker.
Table 3. Pairwise comparison of the nucleotide and deduced amino acid sequences of ORFs 2 and 3 of the swine HEV with human
HEV strains
Virus
strains SHEV Mexico HEV037 Uigh179 Hetian KS2-87 Sar55 Madras Hyderabad Burma NE8L
ORF2
SHEV 79 (90) 80 (91) 80 (91) 80 (91) 80 (92) 80 (92) 79 (92) 79 (90) 79 (92) 79 (91)
Mexico 83 (79) 81 (93) 81 (92) 81 (93) 81 (93) 81 (93) 81 (93) 81 (92) 81 (93) 81 (92)
HEV037 84 (82) 90 (89) 94 (98) 94 (98) 94 (98) 94 (99) 94 (98) 92 (97) 94 (98) 94 (98)
Uigh179 84 (80) 90 (85) 97 (97) 98 (98) 98 (99) 97 (99) 93 (98) 93 (97) 94 (99) 93 (98)
Hetian 84 (80) 90 (85) 97 (97) 98 (97) 99 (99) 98 (99) 93 (98) 93 (97) 94 (99) 93 (98)
KS2-87 84 (80) 90 (85) 97 (97) 98 (98) 98 (97) 98 (99) 93 (99) 93 (98) 94 (99) 94 (98)
Sar55 85 (82) 91 (87) 98 (98) 99 (98) 99 (98) 99 (98) 93 (99) 93 (98) 94 (99) 93 (99)
Madras 85 (82) 90 (87) 98 (98) 98 (98) 98 (98) 98 (98) 99 (100) 96 (98) 97 (99) 96 (98)
Hyderabad 83 (77) 89 (84) 95 (93) 96 (93) 96 (93) 97 (95) 97 (95) 97 (95) 97 (98) 96 (97)
Burma 84 (82) 90 (87) 98 (98) 98 (98) 98 (98) 98 (98) 99 (100) 99 (100) 97 (95) 98 (99)
NE8L 84 (81) 90 (87) 98 (97) 98 (97) 97 (97) 97 (97) 98 (98) 98 (98) 96 (93) 99 (98)
ORF3
The values in the table represent the percentage identity of nucleotide or amino acid (in parentheses) sequences
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human strains of HEV, viremia just prior to seroconversion,
and histologic evidence of hepatitis in the naturally infected
pigs. Because the swine anti-HEV crossreacted with human
HEV capsid antigen, and because the infected piglets had
microscopic evidence of hepatitis during the acute stage of
infection, we have tentatively designated this HEV-related
agent in pigs as swine HEV.
The high prevalence of anti-HEV in commercial swine herds
suggested that swine HEV is widespread in the general swine
population. However, results from the prospective study
showed that the naturally infected young pigs did not display
clinical symptoms, although there was microscopic evidence of
hepatitis, suggesting that swine HEV caused only subclinical
infection in young pigs. This situation is reminiscent of hep-
atitis A virus infection in humans (21). Children infected with
hepatitis A virus are often asymptomatic, but most infected
adults show typical clinical symptoms (21). It is difficult to
evaluate the outcome of natural swine HEV infection in adult
pigs, however, since virtually all swine $3 months of age had
IgG anti-HEV. Experimental infection of adult SPF swine with
swine HEV will likely be necessary to answer this question.
Based on the observed similarities between swine HEV and
human strains of HEV, one cannot yet determine whether
swine HEV is species-specific or is circulating in the human
population. Assessment of anti-HEV prevalence in pig han-
dlers and experimental inoculation of primates with swine
HEV should help address this important question. Subclinical
infection of humans with swine HEV might explain the
relatively high prevalence of anti-HEV in healthy individuals
in the United States, where hepatitis E is not endemic (9).
Development of a differential diagnostic test to distinguish
between infections with swine HEV and human HEV is
necessary.
The amino acid differences between swine and human HEV
in the putative capsid gene are less than 10%. However, the
high degree of amino acid sequence conservation in the capsid
gene among human strains of HEV could argue that the
differences between swine and human HEV may be of func-
tional significance. There are well-documented examples of a
single or few amino acid changes in a structural protein
dramatically altering viral tropism and pathogenicity (22, 23).
FIG. 4. Alignment of the amino acid sequences of ORFs 2 (A) and 3 (B) of swine HEV with human strains of HEV. The sequence of Sar55
strain is shown on top, and only differences are indicated. Deletions are indicated by a minus. The putative hypervariable region (HVR) in the
ORF3 is indicated by asterisks. Sequences used in this alignment were Burma (14), Mexico (15), NE8L (Myanmar, ref. 16), Hyderabad (India, ref.
17), Madras (India, GenBank accession no. X99441), HEV037 (isolate from a case of fulminant hepatitis, GenBank accession no. X98292), Sar55
(Pakistan, ref. 18), KS2-87 (China, ref. 19), Hetian (China, GenBank accession no. L08816), and Uigh179 (China, ref. 20).
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From the evolutionary point of view, it is not clear whether
human HEV evolved from swine HEV, or vice versa, or
whether swine and human HEV diverged from a common
ancestor. Retrospective studies of archived serum samples
from swine and humans may provide some information about
the evolutionary relationship between swine and human HEV.
The possibility that swine HEV may infect humans also
raises a potential public health concern for zoonosis or xeno-
zoonosis. Xenotransplantation of pig organs has been sug-
gested as a solution to the solid organ donor shortage for
transplantations. However, xenozoonoses, the inadvertent
transmission of pathogens from animal organs to human
recipients, is of major concern (24). Viruses pathogenic for
pigs might pose a risk to humans. However, nonpathogenic pig
viruses may also become pathogenic for humans after xeno-
transplantation, as a result of species jumping, recombination,
or adaptation in immunocompromised xenotransplantation
recipients (24). Furthermore, pigs recovered from swine HEV
infection might have a damaged liver (or other organ), which
would limit its usefulness for xenotransplantation.
The discovery of swine HEV opens a new direction in HEV
research and provides an opportunity for a better understand-
ing of HEV pathogenesis. The similarities between swine and
human HEV suggest that swine HEV infection in swine might
provide an alternative animal model for HEV studies. Because
swine HEV is immunologically crossreactive with human HEV
and their capsid genes are very conserved, swine HEV may
also prove useful as an attenuated vaccine for immunization
against human hepatitis E through the ‘‘Jennerian’’ approach.
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FIG. 5. Phylogenetic tree based on the complete nucleotide se-
quences of ORFs 2 and 3. The tree was constructed by maximum
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bound search option. Branch lengths (number given above each
branch) are indicated.
Medical Sciences: Meng et al. Proc. Natl. Acad. Sci. USA 94 (1997) 9865
